BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 137
- Registration Number
- NCT01933152
Japanese BAY88-8223 Monotherapy Phase II Study
Phase 2
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 49
- Registration Number
- NCT01929655
Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes
Phase 4
Completed
- Conditions
- Heartburn
- Interventions
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 559
- Registration Number
- NCT01928888
Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Other: no drug
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 160
- Registration Number
- NCT01928979
Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
Phase 1
Completed
- Conditions
- Chagas Disease
- Interventions
- First Posted Date
- 2013-08-22
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 37
- Registration Number
- NCT01927224
Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator
Phase 2
Completed
- Conditions
- Raynaud Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 23
- Registration Number
- NCT01926847
Effect of Ketoconazole on the Pharmacokinetics of Refametinib
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2014-01-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT01925638
Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients
Completed
- Conditions
- StrokeEmbolism
- Interventions
- Other: Rivaroxaban ( Xarelto, BAY59-7939)
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 209
- Registration Number
- NCT01925755
Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors
Phase 1
Completed
- Conditions
- Hemophilia AHemophilia B
- Interventions
- Drug: BAY Factor VII (BAY86-6150)Drug: Placebo
- First Posted Date
- 2013-08-13
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT01921855
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Phase 2
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT01915602
© Copyright 2025. All Rights Reserved by MedPath